Patients with clinically isolated syndromes (CIS) are prone to develop multiple sclerosis (MS). The randomized, placebo-controlled CHAMPS trial found early treatment with interferon -1a to be ...

In RRMS, the early course of the disease is characterised by intermittent relapses, and partial or complete recovery of function between exacerbations. The occurrence of relapses is a key measure of ...

Compared with moderately effective therapies, initial use of highly effective therapies for pediatric-onset multiple sclerosis (MS) was associated with a reduced risk of relapse, a retrospective ...

Rebif (interferon beta-1a) is a prescription drug used to treat some types of multiple sclerosis (MS). Rebif may be safe to use while pregnant or breastfeeding. Keep ...

MS typically appears in young adulthood, but 3% to 5% of cases have an onset in early childhood or adolescence. No disease-modifying therapies have FDA approval for persons younger than 18 years of ...